EAM Investors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

EAM Investors’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-170,901	Closed	-$1.86M	–	404
2023 Q2	$1.86M	Hold	170,901	–	–	0.34%	117
2023 Q1	$1.18M	Buy	+170,901	New	+$1.07M	0.23%	212
2018 Q1	–	Sell	-48,197	Closed	-$1.57M	–	376
2017 Q4	$1.57M	Buy	48,197 +24,614	+104%	+$663K	0.28%	163
2017 Q3	$554K	Buy	+23,583	New	+$264K	0.07%	275

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

EAM Investors's MRNS Position: Q3 2023 in Review

EAM Investors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 170,901 shares — an estimated $1.86M sold.

EAM Investors first reported a position in MRNS in Q3 2017 and held it in 4 quarters. The position peaked at $1.86M in Q2 2023. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

EAM Investors reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
EAM Investors sold 170,901 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $1.86M.
EAM Investors first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 4 quarters.
EAM Investors's Marinus Pharmaceuticals, Inc position peaked at $1.86M in Q2 2023.
104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on EAM Investors's 13F filing for Q3 2023, filed 13 Nov 2023.